This is the authors' abstract. We don't add key points for this paper.
• E-COS and C-COS restored hematopoietic function in Cyclophosphamide induced immunosuppression. • Organ indices normalized, reversing spleen hypertrophy and thymus/liver atrophy. • Histology showed preserved thymic structure and reduced splenic lymphocyte loss. • Cytokine levels (TNF-α, IL-6, IL-1β) increased, counteracting Cyclophosphamide suppression. • Oxidative stress markers improved, restoring redox balance in treated mice. This study explores the immunomodulatory effects of chito-oligosaccharides (COS) derived from Alcaligenes faecalis chitinase in a cyclophosphamide-induced immunosuppression model in Swiss albino male mice. Mice received cyclophosphamide (80 mg/kg, i.p.) to induce immunosuppression, followed by oral administration of enzymatically derived COS (E-COS) and chemically synthesized COS (C-COS) at 20 mg/kg/day for 15 days. Both E-COS and C-COS significantly increased WBC (4.50 ± 0.71 and 5.37 ± 0.91) and RBC (5.80 ± 0.83 and 5.74 ± 0.86) counts compared to the cyclophosphamide group (1.43 ± 0.49 and 2.54 ± 0.76). Histopathological analysis showed thymic architecture restoration and reduced splenic lymphocyte apoptosis. Additionally, COS treatment elevated proinflammatory cytokine levels (TNF-α, IL-6, IL-1β) and decreased oxidative stress markers (malondialdehyde, glutathione). These findings suggest that COS possess immunomodulatory potential and may counteract cyclophosphamide-induced immunosuppression.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Rajesh et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: